Sarepta Therapeutics' Outperform Rating Reiterated by Oppenheimer

Analysts maintain positive outlook on biotech company's stock despite recent earnings miss.

Mar. 22, 2026 at 6:20am

Got story updates? Submit your updates here. ›

Oppenheimer has reissued its outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT), a biopharmaceutical company focused on developing precision genetic medicines for rare neuromuscular diseases. The analysts have maintained a $37.00 price target on the stock, despite Sarepta reporting weaker-than-expected earnings in its latest quarter.

Why it matters

Sarepta Therapeutics is a key player in the rare disease drug development space, with several approved exon-skipping therapies for Duchenne muscular dystrophy. The company's ability to continue advancing its pipeline and maintain its commercial products is closely watched by investors and the broader biotech industry.

The details

In a research note, Oppenheimer reiterated its outperform rating and $37.00 price target on Sarepta Therapeutics' stock. This comes despite the company reporting a wider-than-expected loss in its latest quarterly earnings. Other analysts have also weighed in, with some raising their price targets while others lowered theirs based on the earnings results. Overall, the majority of analysts covering Sarepta maintain a positive outlook on the stock.

  • Oppenheimer published its research note on Thursday, March 12, 2026.
  • Sarepta Therapeutics reported its latest quarterly earnings on Wednesday, February 25, 2026.

The players

Sarepta Therapeutics

A biopharmaceutical company focused on developing precision genetic medicines for rare neuromuscular diseases, headquartered in Cambridge, Massachusetts.

Oppenheimer

A financial services firm that provides research coverage on Sarepta Therapeutics' stock.

Got photos? Submit your photos here. ›

The takeaway

Despite a recent earnings miss, Sarepta Therapeutics maintains a positive outlook from analysts like Oppenheimer, who see the company's rare disease drug pipeline and commercial products as drivers of future growth.